Inhibitors of lysine specific demethylase-1
AssigneeQuanticel Pharmaceuticals, Inc.
InventorsYoung K. Chen, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Claims53
A compound having the structure of Formula (IV), or a pharmaceutically acceptable salt thereof,
- wherein,
- X and Y are each independently chosen from C—H, C—F, C—CH3, or N;
- Z is chosen -G, —CH2-G, —CH2—CH2-G, —N(R1)-G, —N(R1)—CH2-G, —O-G, —O—CH2-G, or —C(O)N(R2)(R3);
- X1, X2, and X3 are each independently selected from N or C—R4;
- provided that at least one of X1, X2, or X3 is N;
- G is carbocyclyl, aryl, heterocyclyl or heteroaryl;
- R1 is hydrogen or alkyl;
- R2 and R3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R2 and R3 join to form an N-linked heterocyclyl ring system;
- R4 is hydrogen, halogen, C1-C3 alkyl or C1-C3 alkoxy;
- and
- R is aryl, heteroaryl, alkynyl, or cycloalkylalkynylene.
The compound of claim 121 or 22, or pharmaceutically acceptable salt thereof, wherein R1 is hydrogen.
Dependencies are inferred from the claim text.